Background Extracorporeal membrane oxygenation (ECMO) or pumpless extracorporeal
lung assist (pECLA) requires effective anticoagulation. Knowledge on the use of argatroban …

Background: Heparin is the widely used anti-coagulation strategy for patients on
extracorporeal membrane oxygenation (ECMO). Nevertheless, heparin-induced …

Background Heparin-induced thrombocytopenia (HIT) causes thromboembolic
complications which threaten life and limb. Heparin is administered to virtually every …

The objective of this study was to assess the required dose and anticoagulatory effect of
argatroban (Mitsubishi, Pharma Deutschland GmbH, Düsseldorf, Germany), a direct …

Argatroban is a parenteral direct thrombin inhibitor that requires close monitoring to ensure
safety and efficacy. Limited data exist to describe its effect in critically ill patients. This was a …

Purpose: The purpose of this study was to evaluate the cost effectiveness of argatroban
compared to heparin during extracorporeal membrane oxygenation (ECMO) therapy …

Study Objective. To compare the outcomes of reduced‐dose argatroban therapy in patients
in the intensive care unit (ICU) with those of non‐ICU patients. Design. Retrospective …

The current study aims to evaluate whether prophylactic anticoagulation using argatroban or
an increased dose of unfractionated heparin (UFH) is effective in achieving the targeted …

We investigated the anticoagulant effects of argatroban, a direct thrombin inhibitor, versus
heparin in extracorporeal membrane oxygenation (ECMO) circuits. Three sham circuits were …

The patients who do not respond even to very high dosages of heparin are assumed to
suffer from heparin resistance. The aim of this study was to investigate whether critically ill …